Platelet activation and platelet leukocyte aggregates are associated with acute kidney injury after cardiac surgery

Naomi Brown[1], Nikol Sullo[1,2], Bryony Eagle-Hemming, Florence Y. Lai, Sophia Sheikh, Kristina Tomkova, Lathishia Joel-David, Tracy Kumar, Hardeep Aujla, Alison H Goodall, Gavin J Murphy, Marcin J Woźniak[*]

Department of Cardiovascular Sciences and NIHR Cardiovascular Biomedical Research Unit, University of Leicester, Glenfield Hospital, Leicester, UK. LE3 9QP

[1] These authors contributed equally

[2] Current address: Medical School, Swansea University, Swansea, UK

[*]**Address for correspondence:** Dr Marcin J Woźniak Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Wing, Glenfield General Hospital, Leicester, LE3 9QP, UK. Tel: +44 116 258 3028, Email: mw299@leicester.ac.uk

Running title: Circulating extracellular vesicles and miR as biomarkers of AKI

Abstract

We hypothesised that circulating extracellular vesicles (EV) and micro-RNA levels can serve as predictive and diagnostic markers for acute kidney injury (AKI) in patients undergoing cardiac surgery. Plasma samples were collected from patients recruited to the MaRACAS study before, immediately after and 6-12, 24 and 48 hours after the procedure from 95 patients. Particle size distribution and concentrations were measured using NanoSight. EV derivation and platelet and leukocyte activation were measured using flow cytometry. Platelet function was measured with Multiplate, and circulating soluble biomarkers were measured with a MAGPIX device. Micro-RNA assessment was performed with TaqMan arrays in batched samples. Selected micro-RNAs were validated in each sample by qRT-PCR. Our data shows that platelet-derived EVs were higher 24 hours after surgery. TaqMan arrays identified miR-668 downregulated before and miR-92a-1, -920, -518a-3p, -133b and -1262 upregulated immediately after surgery in AKI patients. Validation confirmed that miR-1262 was significantly upregulated after surgery and identified miR-133b as downregulated before surgery. In addition, we showed that platelets were desensitised to ADP 6-12 hours after surgery. There were more platelet-granulocyte aggregates before and 24 hours after surgery, and levels of soluble ICAM1 were higher before surgery in patients with AKI. In conclusion, AKI is associated with platelet activation, suggesting that platelet inhibition treatments may be renoprotective. Furthermore, studies in larger cohorts should verify miR-1262 as a diagnostic marker of AKI.

Keywords: Surgical Procedure, Cardiovascular, Cell-Derived Microparticles, MicroRNAs, Acute Kidney Injury, Biomarkers

Introduction

Acute kidney injury (AKI) is a significant complication of cardiac surgery that independently increases patient morbidity and mortality. The prevalence of AKI following cardiac surgery is up to 30%, which prolongs hospital stays and increases healthcare costs. [1] AKI occurs following an acute decrease in glomerular filtration rate (GFR) driven by injury to renal tubular epithelial cells. Serum creatinine (SCr) and urinary output are used to diagnose AKI. Changes in the former usually become apparent 48 hours after surgery, well after the injury occurs, making it an ineffective method of monitoring AKI development. [2] The mechanisms that underlie AKI are poorly understood, but inflammation and activation of the endothelium and platelets are thought to contribute. [3] No individual biomarker has been established as the gold standard for assessing the risk or diagnosing of AKI in cardiac surgery.

Extracellular vesicles (EVs) are small, membrane-bound particles that are secreted by cells into the extracellular space. Two subtypes of EVs are microvesicles (MV) and exosomes, which are released by the plasma membrane and exocytosis, respectively. EVs are involved in the transfer of proteins specific to their cellular origin. Hence, changes in the concentration of EVs during pathological processes can serve as an indicator for affected tissues or cells. [4]

Micro-RNA (miRNA) are non-coding and highly conserved short RNA oligonucleotides that cells actively secrete or passively release (e.g. dead cells). miRNA are released within EVs or complexed with proteins (AGO-2 or NPM1 [5]) or high-density lipoproteins. [6,7] They can influence the post-transcriptional expression of target genes and serve as a means of intracellular communication. [8] Several miRNAs have been associated with the pathogenesis of AKI, [9,10] and studies have shown miRNAs derived from plasma may be used as novel biomarkers for AKI in both adult [11] and paediatric [12] populations.

We hypothesised that specific EVs derived from different cell types or miRNAs will serve as novel biomarkers of post-surgery AKI. To test this hypothesis, we performed longitudinal measurements from baseline to 48 hours of platelet, leukocyte, and endothelial activation simultaneously with assessments of EV and miRNA in blood, in a cohort of adults undergoing cardiac surgery.

Results

Participants

Screening of 230 cardiac surgery patients identified 150 who were eligible for the study. Out of these, fifty-three declined consent, and two became ineligible after giving consent. Ninety-five patients completed the study (**Fig. 1A**), out of which fifty-four developed post-cardiac surgery AKI. The majority of patients developed stage 1 (n=45), two patients developed stage 2 and 7 patients developed stage 3 AKI (**Fig. 1B**). Patient baseline demographics and intra-operative characteristics, shown in **Table 1**, were not different between the groups. The mean age was 72.8 (non-AKI) and 70.6 (AKI), with 85% being males.

Post-surgery ventilation time (AKI: 13, 10 -17 hours vs non-AKI 9, 7 -14 hours) and length of hospital stay (AKI: 10, 7 -13 days vs 8, 6 -9 days) were significantly higher in AKI patients. As expected, the standard AKI biomarkers were significantly higher in AKI patients 6 – 96 hours after surgery and 12 hours after surgery for SCr and urinary NGAL, respectively (**Fig. 1C** and **eTable 1**).

Extracellular vesicles

There was no difference in total particle concentration between AKI and non-AKI patients (**Fig. 2A**) or particle sizes (**Fig. 2B**). Derivation analysis included EVs from apoptotic cells (annexin V), monocytes (CD14), endothelial cells (CD144 and CD62E), granulocytes (CD16), red cells (CD235a), myeloid cells (CD284), lymphocytes (CD3) and platelets (CD41). We also assayed EVs positive for tissue factor (CD142) and β-integrin. Out of these, only platelet-derived EVs were expressed at significantly higher levels in patients with AKI 24 hours after surgery (**Fig. 2C** and **eTable 1**).

MicroRNAs

To identify AKI-related miRNA, 24 batches of samples collected at three time points (pre, ICU and 24 hours after surgery) were analysed with qRT-PCR arrays capable of analysing 754 human miRNA species. miR-668 was significantly downregulated before surgery, and miRs-92a-1, 920, 518a-3p, 133b, and 1262 were upregulated immediately after surgery (ICU in **Fig, 2D** and **eTable 2**). Expression of these miRNAs was verified in each sample separately before surgery, immediately after and 24 hours after surgery using qRT-PCR. This showed that expressions of miR-668 and miR-518a-3p were below detection level in most samples. However, levels of miR-1262 were significantly higher immediately after surgery in AKI patients, and levels of miR-133b were significantly lower in AKI patients before surgery (**Fig. 2E** and **eTable 1**). No difference was observed for miR-133b immediately after surgery.

Inflammation

The platelet function was analysed with a Multiplate aggregometer using ADP, ASPI and TRAP assays. Only ADP assay demonstrated a difference between groups with significantly reduced aggregation 6-12 hours after surgery in patients with AKI (**Fig. 2F** and **eTable 1**).

Activation of blood cells implicated in the pathogenesis of AKI was measured using flow cytometry. These included leukocyte activation (CD11b), platelet aggregation with monocytes and granulocytes (CD14/CD41 and CD16/CD41, respectively), platelet activation (CD41/CD62P and IIb/IIIa expression) and monocyte activation (CD64/CD163). These identified significantly higher levels of platelet activation (IIb/IIIa expression) 6-12 hours after surgery in AKI patients and higher levels of monocyte/platelets aggregates before surgery, 6-12 and 24 hours afterwards (**Fig. 2G** and **eTable 1**).

Analysis of circulating biomarkers of inflammation included Gro1, cell-free haemoglobin, soluble ICAM1 (sICAM1), IL-6, 8 and 10, MCP3 and TNFα. Out of these, sICAM1 was significantly higher in AKI patients before surgery and 48 hours afterwards (**Fig. 2H** and **eTable 1**).

Out of all significant pre-operative variables, levels of platelet-granulocyte aggregates (CD16/CD41) correlated positively with levels of sICAM1 and negatively with levels of miR-133b. No significant correlation was observed between postoperative (6-12 hrs) variables.

Discussion

Main findings

Longitudinal analysis of cellular activation, inflammatory response, and levels of circulating EV and miRNA has shown a significant elevation of platelet activation and platelet-leukocyte aggregation in cardiac surgery patients who develop AKI. Levels of platelet-granulocyte aggregates (CD16/CD41) were higher pre-surgery and at 6-12 hours and 24 hours post-surgery in the AKI group. This group also had increased levels of activated platelets (expressing IIb/IIIa) and platelet-derived EVs at 6-12 and 24 hours post-surgery, respectively, alongside the diminished ADP-induced platelet aggregation. Moreover, endothelial activation (circulating sICAM1 levels) was higher, and levels of plasma miR-133b were lower at baseline in the AKI group. Both of them correlated with levels of platelet-granulocyte aggregates at baseline. miR-1262 was most differentially expressed in the AKI group immediately after surgery and correlated with pre-operative sICAM1 levels.

Clinical significance

The results demonstrate that platelet activation and platelet leukocyte aggregation are associated with AKI following cardiac surgery. Platelets have been shown to have an important role in experimental AKI, where platelet-granulocyte aggregates facilitate intraglomerular neutrophil recruitment and ROS production. [13] In rodents, platelets guide neutrophils to areas with reduced endothelial integrity like glomeruli, [3] whose glycocalyx is disrupted during AKI. [14] In the current study, endothelial activation and platelet leukocyte aggregates were positively correlated before surgery, suggesting that such priming could increase patients' susceptibility to renal injury.

It remains to be tested whether the endothelial function and miR-1262 are functionally related. However, the miRNA has been associated with mesangial proliferative glomerulonephritis. [15] There is also little known about the role of miR-133b, which correlated negatively with platelet-granulocyte aggregates. It regulates kidney fibrosis by inhibiting connective tissue growth factor [16] and was previously associated with diabetic nephropathy, where its serum levels increase. [17] But no previous studies associated miR-133b with either platelets or granulocytes.

No trial to our knowledge has evaluated the renoprotective effect of anti-platelet agents in cardiac surgery[18,19]. Conversely, multiple RCTs have compared the effects of different anti-platelet agents on vein graft patency rates, arterial thromboses, and bleeding post-surgery. [20] None of these trials reported acute kidney injury event rates. Indirect evidence for a renoprotective effect of platelet inhibition comes from small trials of NO donors or prostacyclin [21–23] that have known anti-platelet effects and improve creatinine clearance after cardiac surgery. Together, these results support the reevaluation of existing trials or new trials of anti-platelet therapy for renoprotection.

Limitations

As in any other study of AKI biomarkers, the major limitation is the use of an unreliable biomarker to define renal injury. [2] More recent biomarkers, such as TIMP-2 and IGFBP7, were shown to be useful diagnostic tools for AKI. However, they are not discriminatory in the cardiac surgery cohort. [10] Another limitation is the use of pooled samples for the initial identification of AKI-associated microRNAs. This was dictated by the budgetary limitations, and analysis of all patients or a selected cohort of patients with well-defined clinical characteristics could potentially result in the identification of more relevant microRNAs. Sample pooling can also be behind the discrepancies in miR-133b expression between discovery and validation. NanoSight, used to estimate particle concentration, does not discriminate between membrane-bound and other particles. Therefore, we are not able to conclude whether the increases in specific particle sizes are associated with platelet-derived EVs. A final limitation is the small size of the study and high levels of missing data for flow cytometry analysis of platelet and leukocyte activation. We cannot be sure that a larger sample or one with different eligibility criteria would not provide a different result.

Conclusions

Our analysis does not support EVs and miRNAs as predictive biomarkers of AKI. However, miR-1262 has a diagnostic potential and needs to be validated in a larger cohort. Furthermore, platelet activation and platelet leukocyte aggregates are associated with post-cardiac surgery AKI, suggesting that more effective platelet inhibition may be renoprotective. [3]

Methods

Study design and setting An Observational Case Control Study to Identify the Role of MV and MV Derived Micro-RNA in Post CArdiac Surgery AKI (MaRACAS) was a prospective, single-centre observational study approved by East Midlands - Leicester South Research Ethics Committee (REC reference 13/EM/0383) conducted between 11th December 2014 and 30th May 2017 in Glenfield General Hospital in Leicester, UK. The protocol was registered at https://clinicaltrials.gov/ct2/show/NCT02315183.

Study cohort included prospectively recruited 95 consecutive adult cardiac surgery patients (> 16 years old) undergoing coronary artery bypass grafting or valve surgery with moderately hypothermic cardiopulmonary bypass (32 – 34 ˚C) blood cardioplegia. All participants were identified as at increased risk for AKI using a modified risk score. [18] Exclusion criteria included: pre-existing inflammatory state, ejection fraction <30%, Kidney Disease: Improving Global Outcomes stage 3 AKI, requirement for ionotropes, ventilation or intra-aortic balloon pump, and pregnancy.

Blood sampling, storage and bias Blood was collected pre-operatively, on return to the intensive care unit, and 6–12, 24, 48, 72 and 96 hours post-operatively. The total volume collected from each patient was 104.8 ml divided between clotting, EDTA, citrate and hirudin tubes (S-Monovette, Sarstedt, Nuembrecht, Germany). Urine was collected before surgery and 6, 12 and 24 hours after. Times and volumes were recorded. All samples were processed within 2 hours after collection and frozen at -80 ˚C for further analysis. Samples were identified by a trial acronym and the patient's study ID. Routine measurements, including serum creatinine, were performed in NHS laboratories by personnel who were unaware that the participant was in a trial. For all other analyses, laboratory staff was blinded to the AKI status of patients.

Outcomes AKI and stages of AKI were determined according to the Kidney Disease Improving Global Outcomes (KDIGO) definition. [24] Secondary outcomes included levels of urinary NGAL, serum creatinine, soluble biomarkers including circulating biomarkers Gro1, IL-6, -8 and -10, MCP3, TNFα, ICAM1 and haemoglobin; total particle concentrations, fractions of EV positive for Annexin V, CD235a, CD41, CD144, CD142, CD14, CD16 CD284, CD3, and CD29; platelet and monocyte activation and miRNA expression.

Soluble biomarker analysis NGAL measurements were performed in urine using a Human Lipocalin-2/NGAL Quantikine ELISA kit (BioTechne). Levels of soluble circulating biomarkers, Gro1, IL-6, -8 and -10, MCP3, TNFα and sICAM1 were measured by multiplex assay on the MAGPIX Analyser (Luminex, Netherlands). Plasma-free haemoglobin was estimated as described in Fairbanks et al. [25] Briefly, the samples were spun at 1,800 xg for 15 min, and the resulting supernatant was further spun for 5 min at 20,000 xg. The supernatant was diluted 5x with PBS, and absorbance was

measured at 415nm, 450nm and 700nm using Multiplate reader Enspire (PerkinElmer). Haemoglobin concentration was calculated as follows: Hb = 1.58xA415 - 0.95xA450 - 2.91xA700.

EV analysis was performed in citrated plasma samples spun twice at 1,500 × g and stored at –80°C. Concentration and size distribution were estimated using NanoSight NS500, nanoparticle tracking device (Malvern Instruments, Malvern, United Kingdom). Derivation of microvesicles was determined with fluorescently labelled annexin V or antibodies against CD235a, CD41, CD144, CD142, CD14, CD16 CD284, CD3, and CD29 (all ThermoFisher). Samples (20–50 µL) were labeled with antibodies at 1:20 dilution in phosphate-buffered saline for 25 minutes at room temperature (RT) in a total volume of 100 µL. The samples were analysed by flow cytometry (Cyan ADP; Beckman Coulter, Brea, CA).

MicroRNA analysis RNA from EVs were isolated from circulating blood using exoRNeasy kit (Qiagen) using the manufacturer's instructions. RNA (100 ng) was reverse transcribed using the Taq-Man Multiplex RT set for TaqMan Array Human MicroRNA Panel v2.0 (Applied Biosystems, Foster City, USA) and Veriti thermal cyclers. Pre-amplified complementary DNA from each pool was analysed using TaqMan Array Human MicroRNA Card A and B v2.0 (Applied Biosystems). Quantitative polymerase chain reaction was carried out on an Applied BioSystems 7900HT thermocycler. The experiments were performed in triplicates. Any assays where the cycling threshold (Ct) value was lower than 20 were removed, and ΔCt (difference in cycling threshold) values were calculated (ΔCt = miRNA Ct–reference miRNA Ct) using reference control U6 snRNA-001973 present in duplicates on each miRNA array. Undetermined assays were assigned maximum cycling value. Data were normalised across arrays using quantile normalisation. Differential expression analysis was performed with *limma* R package. [26]

Selected differentially expressed miRNAs were analysed using rotor-gene (Qiagen) quantitative real-time PCR instruments in samples from all patients using TaqMan Advanced miRNA assays for hsa-miR-17, hsa-miR-223, hsa-miR-486, hsa-miR-668, hsa-miRs-92a-1, hsa-miRs-920, hsa-miRs-518a-3p, hsa-miRs-133b and hsa-miRs-1262 (ThermoFisher) according to the manufacturer's recommendations. The data was standardised against levels of hsa-miR-17, hsa-miR-223 and hsa-miR-486, which showed constant expression levels across all time-points and patient groups.

Leukocyte and platelets activation was estimated by flow cytometry (Cyan ADP, Beckman Coulter, Brea, CA) in citrated blood samples. For leukocyte analysis, red cells in 100 µL of whole blood were lysed with FACS Lysing Solution (BD Biosciences, Oxford, UK) for 10 min at RT. Leukocytes were labelled with FITC-coupled CD64, CD11b, CD16, CD14, and PE-coupled CD163 (Affymetrix, Santa Clara, CA) antibodies at 1:20 dilution for 25 min at room temperature (RT). For platelets 5 µL of whole blood was labelled with FITC-coupled PAC-1 (BD Biosciences), CD62E (Abcam,

Cambridge, UK) and PE-coupled CD41 (Affymetrix) antibodies at 1:20 dilution at RT for 25 min in a total volume of 100 μL.

Statistical analysis was performed using R Studio Version 4.3.1 [27] and plots prepared with ggplot R package. [21] Data normality was assessed using the Shapiro-Wilk test, with normally distributed variables expressed as mean (± standard deviation [SD]) and non-normally distributed variables expressed as median (interquartile range [IQR]). Analyses were performed between patients with AKI and without AKI. Comparisons of miRNA analysed with PCR-arrays and EV size were adjusted for multiple comparisons using Benjamini-Hochberg method. Pre-specified outcomes were not adjusted for multiple comparisons. [28–30]

References

1. Lagny, M.-G. *et al.* Incidence and outcomes of acute kidney injury after cardiac surgery using either criteria of the RIFLE classification. *BMC Nephrol* **16**, 76 (2015).
2. Harky, A. *et al.* Acute Kidney Injury Associated with Cardiac Surgery: a Comprehensive Literature Review. *Braz J Cardiovasc Surg* **35**, 211–224 (2020).
3. Jansen, M. P. B., Florquin, S. & Roelofs, J. J. T. H. The role of platelets in acute kidney injury. *Nat Rev Nephrol* **14**, 457–471 (2018).
4. Oh, S. & Kwon, S. H. Extracellular Vesicles in Acute Kidney Injury and Clinical Applications. *Int J Mol Sci* **22**, (2021).
5. Arroyo, J. D. *et al.* Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc Natl Acad Sci U S A* **108**, 5003–5008 (2011).
6. Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D. & Remaley, A. T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. *Nat Cell Biol* **13**, 423–433 (2011).
7. Wang, J.-X. *et al.* MicroRNA-103/107 Regulate Programmed Necrosis and Myocardial Ischemia/Reperfusion Injury Through Targeting FADD. *Circulation Research* **117**, 352–363 (2015).
8. Creemers, E. E., Tijsen, A. J. & Pinto, Y. M. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? *Circ Res* **110**, 483–495 (2012).
9. Fan, P. C., Chen, C. C., Chen, Y. C., Chang, Y. S. & Chu, P. H. MicroRNAs in acute kidney injury. *Hum Genomics* **10**, 29 (2016).
10. Miller, D. *et al.* Urinary extracellular vesicles and micro-RNA as markers of acute kidney injury after cardiac surgery. *Sci Rep* **12**, 10402 (2022).
11. Fan, P. C. *et al.* A circulating miRNA signature for early diagnosis of acute kidney injury following acute myocardial infarction. *J Transl Med* **17**, 139 (2019).
12. Sullo, N. *et al.* An Observational Cohort Feasibility Study to Identify Microvesicle and Micro-RNA Biomarkers of Acute Kidney Injury Following Pediatric Cardiac Surgery. *Pediatr Crit Care Med* **19**, 816–830 (2018).
13. Singbartl, K., Forlow, S. B. & Ley, K. Platelet, but not endothelial, P-selectin is critical for neutrophil-mediated acute postischemic renal failure. *FASEB J* **15**, 2337–2344 (2001).
14. Qureshi, S. H., Pate, N. N. & Murphy, G. J. Vascular endothelial cell changes in postcardiac surgery acute kidney injury. *American journal of physiology. Renal physiology* **314**, F726–F735 (2018).
15. Dai, R. *et al.* Differential expression profile of urinary exosomal microRNAs in patients with mesangial proliferative glomerulonephritis. *Aging (Albany NY)* **15**, 866–880 (2023).

16. Cao, D. *et al*. Regulation of connective tissue growth factor expression by miR-133b for the treatment of renal interstitial fibrosis in aged mice with unilateral ureteral obstruction. *Stem Cell Research & Therapy* **12**, 171 (2021).
17. Zhang, X.-L. *et al*. LncRNA CASC2 regulates high glucose-induced proliferation, extracellular matrix accumulation and oxidative stress of human mesangial cells via miR-133b/FOXP1 axis. *Eur Rev Med Pharmacol Sci* **24**, 802–812 (2020).
18. Pathak, S. *et al*. Pharmacological interventions for the prevention of renal injury in surgical patients: a systematic literature review and meta-analysis. *Br J Anaesth* **126**, 131–138 (2021).
19. Abbasciano, R. G. *et al*. Activation of the innate immune response and organ injury after cardiac surgery: a systematic review and meta-analysis of randomised trials and analysis of individual patient data from randomised and non-randomised studies. *Br J Anaesth* **127**, 365–375 (2021).
20. Sandner, S. *et al*. Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery: A Systematic Review and Meta-analysis. *JAMA* **328**, 554–562 (2022).
21. Darcin, O. T. *et al*. Effect of iloprost on renal function in patients undergoing coronary artery bypass grafting: a clinical study. *Ann Thorac Cardiovasc Surg* **19**, 12–17 (2013).
22. Lei, C. *et al*. Nitric Oxide Decreases Acute Kidney Injury and Stage 3 Chronic Kidney Disease after Cardiac Surgery. *Am J Respir Crit Care Med* **198**, 1279–1287 (2018).
23. Kaya, K. *et al*. The effect of sodium nitroprusside infusion on renal function during reperfusion period in patients undergoing coronary artery bypass grafting: a prospective randomized clinical trial. *Eur J Cardiothorac Surg* **31**, 290–297 (2007).
24. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney inter*., *Suppl*. **2**, 1–138 (2012).
25. Fairbanks, V. F., Ziesmer, S. C. & O'Brien, P. C. Methods for measuring plasma hemoglobin in micromolar concentration compared. *Clin Chem* **38**, 132–140 (1992).
26. Ritchie, M. E. *et al*. limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res* **43**, e47 (2015).
27. {R Core Team}. R: A Language and Environment for Statistical Computing. (2018).
28. Rothman, K. J. No adjustments are needed for multiple comparisons. *Epidemiology* **1**, 43–46 (1990).
29. Saville, D. J. Multiple Comparison Procedures: The Practical Solution. *The American Statistician* **44**, 174–180 (1990).
30. Ridker, P. M. *et al*. C-reactive protein levels and outcomes after statin therapy. *N Engl J Med* **352**, 20–28 (2005).

Authors' contributions

Individual contributions to the study were as follows: GJM, MJW and AHG designed the study, MJW and NB wrote the manuscript. LJ-D, TK and HA managed the conduct of the study. NS, BE-H, SS and KT collected samples and data. NB, NS, FYL and MJW performed statistical analyses.

Funding

British Heart Foundation (RG/13/6/29947), (CH/12/1/29419) to GJM, MW, TK, and HA; Leicester and Bristol National Institute for Health Research Cardiovascular Biomedical Research Units.

Competing interests

Prof. Murphy received grants from Terumo and Baxter. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Table 1 – Baseline and intraoperative characteristics in the analysed cohort. Tests between groups were conducted by exact test for categorical variables and T-test or Wilcoxson test for continuous variables. Data are presented as n (%) for categorical variables and mean (standard deviation, STD) or median (interquartile range, IQR) for continuous variables. Abbreviations: AKI – Acute Kidney Injury; CABG – Coronary artery Bypass Grafting; CCS – Canadian Cardiovascular Society; NYHA – New York Heart Association; BMI – Body Mass Index; eGFR - estimated Glomerular Filtration Rate; LOS – Length Of Stay; ICU – Intensive Care Unit; AST - Aspartate Aminotransferase; ALT - Alanine Transaminase; ALP - Alkaline phosphatase; GGT - Gamma-glutamyl Transferase, MODS – Multiple Organ Dysfunction Score.

	non-AKI (n = 41)	AKI (n = 54)	*p*-value
Age (years)	70.6 (6.9)	72.8 (7.6)	0.151
Sex - Male	35 (85.4%)	46 (85.2%)	0.980
Caucasian	41 (100.0%)	52 (96.3%)	0.504
BMI	31.7 (5.2)	31.4 (6.1)	0.745
Surgery type			
CABG	19 (46.3%)	19 (35.2%)	0.324
Valve	15 (36.6%)	19 (35.2%)	
both/others	7 (17.1%)	16 (29.6%)	
Medical history			
Diabetes	20 (48.8%)	31 (57.4%)	0.416
Chronic kidney disease	9 (22.0%)	11 (20.4%)	0.852
Myocardial infarction	7 (17.1%)	10 (18.5%)	0.856
Stroke	5 (12.2%)	8 (14.8%)	0.713
Chronic pulmonary disease	1 (2.4%)	2 (3.7%)	0.999
Previous cardiac surgery	2 (4.9%)	4 (7.4%)	0.696
smoker			
Current	12 (30.0%)	22 (42.3%)	0.478
Ex-smoker	18 (45.0%)	19 (36.5%)	
Never	10 (25.0%)	11 (21.2%)	
NYHA			
class I	5 (12.2%)	8 (14.8%)	0.491
class II	29 (70.7%)	32 (59.3%)	
class III & IV	7 (17.1%)	14 (25.9%)	
CCS			
asymptomatic	11 (27.5%)	24 (44.4%)	0.110
class I	10 (25.0%)	11 (20.4%)	
class II	16 (40.0%)	19 (35.2%)	
class III	3 (7.5%)	0 (0.0%)	
Left ventricular ejection fraction (LVEF)			
Good (>49%)	24 (63.2%)	35 (67.3%)	0.682

Fair(30-49%)	14 (36.8%)	17 (32.7%)	
Left main stem diseased	4 (10.3%)	9 (17.3%)	0.342
Extent of coronary disease			
Normal	6 (15.4%)	11 (21.2%)	0.287
1VD	11 (28.2%)	9 (17.3%)	
2VD	8 (20.5%)	6 (11.5%)	
3VD	14 (35.9%)	26 (50.0%)	
Serum Troponin I	20 (15 -26)	15 (15 -27)	0.627
Heart rate (bpm)	68.9 (12.4)	66.4 (11.7)	0.328
Mean arterial pressure (mmHg)	98.7 (11.9)	97.5 (14.4)	0.674
Haemoglobin (g/dL)	13.3 (1.7)	12.9 (1.4)	0.246
Haematocrit (%)	39.1 (4.7)	38.3 (4.0)	0.418
White blood cells ($x10^9$/L)	7.9 (1.8)	8.1 (1.9)	0.623
Platelets ($x10^9$/L)	225.6 (76.8)	214.9 (50.9)	0.457
eGFR (ml/min/1.73m2)	82.4 (30.1)	78.2 (22.4)	0.453
Albumin (g/L)	40.5 (2.3)	40.6 (3.6)	0.825
Bilirubin (u mol/L)	13.1 (5.0)	13.1 (6.5)	0.992
MODS	0 (0-1)	0 (0-1)	0.76
AST (IU/L)	23.0 (4.8)	25.1 (7.1)	0.107
ALT (IU/L)	24.1 (11.0)	24.8 (9.9)	0.760
ALP (IU/L)	80.1 (26.5)	83.1 (31.9)	0.634
GGT (IU/L)	24 (18 -34)	32 (19 -58)	0.086
CBP time (min)	93 (82 -109)	106 (82 -139)	0.117
CrossClampTime (min)	55 (46 -77)	65 (47 -97)	0.259
Ventilation time (hour)	9 (7 -14)	13 (10 -17)	**0.001**
ICU stay (hour)	27 (25 -53)	48 (25 -93)	0.080
Hospital LOS (day)	8 (6 -9)	10 (7 -13)	**0.017**

Figure legends

Figure 1 – (**A**) CONSORT diagram. (**B**) Bar plot showing patients with AKI stages. (**C**) Levels of serum creatinine and urinary NGAL. Asterisks indicate a significant difference between no-AKI and AKI ($p<0.05$).

Figure 2 – (**A**) Total particle concentrations in citrated plasma. (**B**) Mean size distribution of particle concentrations (+/- SD). (**C**) Plot of EVs positive for platelet marker CD41. (**D**) Bar plot showing log fold difference in miRNA identified by qRT-PCR arrays between AKI and non-AKI. Only miRNA with adjusted *p*-value<0.05 are shown (see **eTable 2** for details). (**E**) Box plot of validation results for miR-133b and miR-1262. (**F**) Box plot of aggregation units acquired using Multiplate ADP assay. (**G**) Box plot of mean expression values for IIb/IIIa detected with PAC-1 antibody in flow cytometry. (**H**) Box plot of sICAM1 concentrations in citrated plasma acquired with a MAGPIX device. (**I**) Correlations (Spearman) between significant preoperative variables and ICU miR-1262, and between significant variables 6-12 hr after surgery. Blue circles indicate significant positive and red circles negative correlation. Asterisks indicate a significant difference between AKI and non-AKI groups ($p < 0.05$)

Figure 1

A


Screened patients: n = 230
Did not meet inclusion criteria: n = 80
Patients approached for consent: n = 150
Declined consent: n = 53
Informed consent signed: n = 97
Did not undergo surgery: n = 1
Became ineligible due to change of the procedure: n = 1
Patients in the study: n = 95
Completed the study:
n = 95
Patients died: n = 2
Protocol violation: n = 0
Lost to follow-up: n = 0
Blood sample collection:
Pre-op: 100%
ICU: 100%
6-12 hrs: 98.9%
24 hrs: 100%
48 hrs: 96.8%
72 hrs: 96.8%
Urine sample collection:
Pre-op: 96.9%
6 hrs: 93.75%
12 hrs: 87.5%
24 hrs: 86.46%
AKI
N=54
non-AKI
N=41
Data completness:
Creatinine: 95.9%
Extracellular vesicles: 93.1%
microRNA: 95.5%
Platelet activation: 73.5%
Leukocyte activation: 65.6%
Cytokines: 95.6%
Data completness:
Creatinine clearance: 79.4%
NGAL: 91.2%

B


Stage
0
1
2
3
Number of patients
0
20
40
AKI
no AKI

C


AKI
non-AKI
Serum Creatine
Urinary NGAL
100
200
300
400
500
0
pre
ICU
6hr
24hr
48hr
72hr
96hr
12hr

Figure 2


A
Particle concentration
Particles x 10^8/mL
pre ICU 6-12hr 24hr 48hr
C
Platelets MV (CD41 pos)
log(% positive MV)
B
Particle size distribution
AKI
non-AKI
pre
ICU
6-12hr
24hr
48hr
Particles x 10^6/mL
Size [nm]
D
hsa−miR−668
hsa−miR−92a−1
hsa−miR−920
hsa−miR−518a−3p
hsa−miR−133b
hsa−miR−1262
logFC
E
hsa-miR-1262
hsa-miR-133b
ΔCT
pre ICU 24hr
F
Multiplate ADP
Aggregation units
G
IIb/IIIa-positive platelets
% positive
H
sICAM1
pg/mL
CD16/CD41 positive
I
sICAM1
CD16/CD41
hsa-miR-1262
hsa-miR-133b
IIb/IIIa
ADP
SCr
pre/ICU
6-12hr